What is TDM-105795, and why is it being studied as a potential product for hair loss and hair growth support?

TDM-105795 is an experimental small molecule drug candidate being developed for the treatment of androgenetic alopecia—a medical term for the most common form of hair loss, often called male-pattern or female-pattern hair loss. So far it has been tested only in men. Unlike shampoo ingredients or cosmetic products, TDM-105795 is being studied as a medicinal, topical solution with the potential to stimulate biological processes in hair follicles that may encourage hair growth. The compound is not yet an approved treatment and remains under clinical investigation by the biotechnology company Technoderma Medicines, Inc. in formal human studies.

Scientific research into hair loss includes a wide variety of strategies; among them are pharmaceuticals that influence hormones, blood flow, or cellular signals within hair follicles. TDM-105795 represents a new class of investigational compounds designed to interact with specific cellular receptors in the skin, potentially affecting how hair follicle stem cells behave and how the hair growth cycle progresses.

How Does TDM-105795 Work? Exploring Its Biological Mechanism

The developer and a 2025 review describe TDM-105795 as a thyromimetic compound (a thyroid-receptor β1 agonist). This means it works by mimicking the effects of thyroid hormones—natural chemical messengers in the body that influence metabolism, growth, and regeneration. Hair follicles are influenced by thyroid signaling, and laboratory research, largely in cultured follicles and animals, suggests that thyroid hormone pathways play a role in the activation and regeneration of cells within hair follicles. When thyroid pathways are imbalanced, hair cycling can be disrupted, delaying the transition from the resting phase (telogen) to the growth phase (anagen), which is essential for healthy hair renewal.

Biologically, hair follicles go through a cycle: anagen (active growth), catagen (transitional phase), and telogen (resting phase). Many common hair loss conditions involve the shortening of anagen and prolongation of resting periods, leading to gradual thinning. Compounds that can push follicles out of resting phases and back into growth could, in theory, improve hair density over time. While TDM-105795’s exact molecular mechanisms have not yet been published in peer-reviewed scientific journals, the clinical development protocols describe its intended action as stimulating dormant follicle cells and prompting the onset of anagen growth when applied topically.

What Research Has Been Done on TDM-105795?

The most substantive source of data for TDM-105795 comes from a Phase 2a clinical trial—a mid-stage study designed to measure safety and initial evidence of effectiveness in human subjects. This study was titled “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia" Across thirteen clinical sites in the United States, this investigation enrolled 71 men aged 18 and older with mild to moderate androgenetic alopecia. Participants applied the topical solution daily for 16 weeks. It followed two Phase 1 safety studies in men (NCT04913519, 30 men; NCT05244980, 32 men).

Efficacy was assessed through non-vellus Target Area Hair Count (TAHC)—a measure of hair density in a defined scalp area that focuses on thicker, terminal hairs rather than thin vellus hairs. Results posted on ClinicalTrials.gov (NCT05802173, November 2025) report a mean change in non-vellus hair count at 16 weeks of +20.3 (0.0025%), +22.4 (0.02%) and +14.0 (vehicle) hairs per cm², with wide spread between participants and no statistical comparison posted. The sponsor's press release gives +24.3 for the 0.02% arm. The data have not been published in a peer-reviewed journal.

The sponsor's press release states both strengths were well tolerated with "extremely low to no systemic exposure"; the registry reports no serious adverse events in 16 weeks (NCT05802173). Long-term safety is unknown.

In addition to human clinical trials, patent filings by the developer describe mouse experiments (e.g., in C3H mice) in which topical application of its compounds was followed by dose-dependent hair regrowth over several weeks. Patent data are not peer-reviewed. These animal studies provide early evidence of biological activity but cannot fully predict outcomes in humans.

A Critical Look at the Evidence So Far

The Phase 2 trial showed larger average hair-count gains in the active arms than on vehicle, but several important limitations remain. First, the results have so far only been posted on the trial registry and in a press release, not in peer-reviewed scientific publications, and no test of whether the difference is statistically significant has been posted. Studies published in journals undergo independent review by other scientists, which strengthens confidence in their methodology and interpretation. The absence of such publication means the data cannot yet be independently confirmed.

Second, no trial has compared TDM-105795 with minoxidil or finasteride, so its size of effect relative to them is unknown (NCT05802173 was vehicle-controlled only).

Scientific reviewers of novel hair therapies generally caution that early trials with short durations (e.g., 16 weeks) may not capture long-term effectiveness or safety. Hair growth cycles can span many months, and changes might continue beyond the timeframe of initial studies. Whether TDM-105795 provides benefits that are maintained or amplified over longer use remains unknown. Additionally, the role of thyroid hormone pathways in hair biology is complex: while some thyroid-related compounds may stimulate hair follicle cells, others could have unclear systemic effects if absorbed. The sponsor reports low absorption, but no thyroid-function results and no long-term human safety data are publicly available.

Finally, while animal studies demonstrate certain dose responses in mice, mouse hair cycles are different from human hair cycles. Mice have synchronized hair growth across skin regions, whereas human hair follicles cycle independently. This difference limits how directly animal results can be translated into human expectations.

Why TDM-105795 Matters in Hair Loss Research

TDM-105795 is one of several experimental approaches that aim to treat hair loss without acting on androgen hormones. Many current treatments influence hormones such as dihydrotestosterone (DHT) or act through broad mechanisms like increasing scalp blood flow. TDM-105795’s approach—targeting thyroid-related pathways and potentially follicle stem cell activation—could contribute to a deeper understanding of how **hair cycles can be pharmacologically regulated. It may also lead to the development of improved molecules or combination therapies that complement existing options.

Ultimately, TDM-105795’s journey from clinical research phase to potential approved therapy will depend on ongoing and future studies, including longer treatment durations, larger participant populations, and independent publication of clinical data. Until then, it remains an emerging candidate rather than an established treatment option.

References

Technoderma Medicines, Inc. press release on Phase 2a trial results (2024). Technoderma Medicines phase 2 clinical trial of TDM-105795 demonstrates hair growth in androgenetic alopecia. PR Newswire. http://www.prnewswire.com/news-releases/technoderma-medicines-phase-2-clinical-trial-of-tdm-105795-demonstrates-hair-growth-in-androgenetic-alopecia-302052631.html

ClinicalTrials.gov. NCT05802173: A randomized, double-blind, vehicle-controlled, parallel group, multi-dose study to evaluate the efficacy and safety of TDM-105795 in male subjects with androgenetic alopecia (results posted 12 November 2025). https://clinicaltrials.gov/study/NCT05802173

ClinicalTrials.gov. NCT04913519 and NCT05244980: Phase 1 studies of TDM-105795 in male subjects with androgenetic alopecia. https://clinicaltrials.gov/study/NCT04913519 · https://clinicaltrials.gov/study/NCT05244980

Kim, J., Song, S. Y., & Sung, J. H. (2025). Recent advances in drug development for hair loss. International Journal of Molecular Sciences, 26(8), 3461. https://doi.org/10.3390/ijms26083461

Technoderma Medicines Pte Ltd. Small molecule compound and synthesizing method and uses thereof. Patent application US20170158651A1. https://patents.google.com/patent/US20170158651A1/en

Technoderma Medicines Pte Ltd. Micromolecule compound, method of synthesis and application thereof. Patent application EP3181556A1. https://patents.google.com/patent/EP3181556A1/en